NDAORALTABLETPriority Review
Approved
Jan 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
11
Mechanism of Action
Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (5)
Avapritinib Rollover Study
Started Nov 2024
60 enrolled
Mastocytosis, Systemic
Avapritinib With Decitabine in Patients With SM-AHN
Started Mar 2024
34 enrolled
Systemic Mastocytosis With an Associated Hematologic Neoplasm
A Drug-drug Interaction Study of Avapritinib and Midazolam
Started Aug 2022
10 enrolled
Gastrointestinal Stromal TumorsGISTNon-resectable Advanced Solid Tumors+1 more
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Started Feb 2022
29 enrolled
Solid Tumor, Unspecified, ChildRelapsed Solid NeoplasmCNS Tumor
Study for Patients Previously Treated in Avapritinib Clinical Trials
Started May 2021
2 enrolled
Gastrointestinal Stromal Tumors
Loss of Exclusivity
LOE Date
Mar 8, 2042
194 months away
Patent Expiry
Mar 8, 2042
Exclusivity Expiry
May 22, 2030